<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01231386</url>
  </required_header>
  <id_info>
    <org_study_id>09147</org_study_id>
    <nct_id>NCT01231386</nct_id>
  </id_info>
  <brief_title>MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced &amp; Inflammatory Breast Cancer</brief_title>
  <official_title>MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced &amp; Inflammatory Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MicroRNAs (MiRNAs) regulate the translation of RNAs and are implicated in cell proliferation
      and renewal both under physiologically normal as well as in malignant conditions.
      Dysregulation of specific miRNAs may be associated with either gaining oncogenic or loosing
      tumor suppressing functions.  MiRNA dysregulation has been implicated in breast cancer
      tumorigenic (stem cell) and non-tumorigenic development.  Therefore, miRNA profiling of
      treatment na√Øve and treatment-exposed breast tumors and sequential samples of blood/serum
      will allow for identification of miRNA markers of prognosis and as indicators and potential
      targets for personalized therapies.  In this proposal, specimens from patients treated in
      the clinical breast cancer program on already existing protocols (IRB 05091 and 05015) will
      be characterized by Dr. Rossi's laboratory and collaborators, and the information gained
      will be applied to develop specific therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current neoadjuvant or adjuvant treatment strategies do not allow for rationale
      incorporation of such agents.  One needs tools to predict both de novo and acquired
      resistance to therapeutic agents.  This is a difficult task, due to the compound nature of
      escape routes: tumor exposure is usually to a combination of therapeutic agents and the
      mechanisms of resistance are broad: intrinsic resistance due to existing mutations, or
      regulatory - miRNA, other epigenetic - alterations,  polymorphisms, tumor cell adaptation
      via new mutations and activation of alternative pathways, lack of optimal
      pharmacokinetics/genomics, activation of efflux mechanisms, accelerated repair mechanisms
      are involved.

      Similarly, not all patients who are candidates for primary surgical intervention to be
      followed by post-operative adjuvant therapy benefit from such systemic treatments.  The
      mechanisms of resistance be it de novo in surviving stem cell/tumorigenic components, or
      acquired by cells  left behind &quot;dormant&quot; after the surgical intervention, are not well
      delineated.

      Breast tumors subjected to neoadjuvant chemotherapy allow for baseline and
      treatment-effected sampling.  Characterization of core biopsy specimens of primary tumors
      procured prior to exposure to neoadjuvant therapy from different varieties of breast cancer
      subtypes, and of subsequent mid-treatment and intraoperative (procured during definitive
      surgery following completion of neoadjuvant therapy) samples should help to assess the
      predictive value of the pre-treatment and post-treatment miRNA expression profile for
      complete and near complete response, as a surrogate marker for survival.  Similarly,
      patterns of de novo and acquired resistance may emerge when assessment of pre- and post
      treatment miRNA expression profiles are analyzed in a supervised manner of classification
      using pathological response as classifier.  Samples obtained from patients with primary
      surgical removal of their tumors before any systemic treatment exposure on the other hand,
      will allow for determining markers of prognosis, and predictors for response to therapeutic
      targeting agents.

      Time Perspective: Retrospective/Prospective
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model:  Cohort</study_design>
  <primary_outcome>
    <measure>Performance of miRNA profiling from tumor samples from primary breast tumors</measure>
    <time_frame>3 years after completion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of miRNA profiles from blood/serum samples from patients at baseline, and if feasible, at different time points</measure>
    <time_frame>3 years after completion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of miRNA findings and correlate miRNA patterns of expression in tumor, lymph nodes -if available- and in serum</measure>
    <time_frame>3 years after competion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of classic tumor markers such as estrogen and progesterone receptor (ER,PR), and HER2 expression with tumor stage and grade</measure>
    <time_frame>3 years after completion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of specific miRNA functions</measure>
    <time_frame>3 years after completion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of ability to knock down functionally relevant overexpressed miRNAs by miR-sponge/antagomirs</measure>
    <time_frame>3 years after completion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Design of prospective pilot phase I-II trials to interfere with dysfunctional/dysregulated miRNA expression</measure>
    <time_frame>3 years after completion of sample collection</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Breast Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissue and Blood Procurement. Breast cancer tissues from core biopsies (as available,
      preferably fresh frozen or RNA-later preserved, but in case of lack of availability,
      formalin-fixed paraffin-embedded [FFPE] core or tissue samples) which have been collected or
      will be collected under IRB#05091 or 05015.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Female, Breast Cancer, &gt; 18 years, regardless of histology, treatment phase, or stage.
        However, only patients with Stage II-III disease from IRB #05015  will be accrued, in
        order to assure that sufficient tumor tissue will be available.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female,

          -  Breast Cancer

          -  &gt; 18 years,

          -  regardless of histology, treatment phase, or stage

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Somlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Somlo, MD</last_name>
    <phone>800 826-4673</phone>
    <email>gsomlo@coh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Kirschenbaum</last_name>
      <phone>800-826-4673</phone>
      <email>mkirschenbaum@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Swain-Cabriales, RN</last_name>
      <phone>800 826-4673</phone>
      <email>sswain-cabriales@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>George Somlo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 22, 2011</lastchanged_date>
  <firstreceived_date>October 27, 2010</firstreceived_date>
  <responsible_party>
    <name_title>George Somlo MD</name_title>
    <organization>City of Hope Medical Center</organization>
  </responsible_party>
  <keyword>Female Breast Cancer</keyword>
  <keyword>miRNA expression</keyword>
  <keyword>Neoadjuvant/Adjuvant Treatment</keyword>
  <keyword>Locally and Inflammatory Breast Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adjuvants, Immunologic</mesh_term>
  </intervention_browse>
</clinical_study>
